Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of ABBV-623 and ABBV-992 in Subjects With B-cell Malignancies

NCT04804254 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04804254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04804254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of ABBV-623 and ABBV-992 in Subjects With B-cell Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
April 27, 2021
Completion date
January 11, 2023
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma